FOURTH-QUARTER
AND FULL-YEAR
2021 RESULTS
TOTAL COMPANY
BUSINESS HIGHLIGHTS
WORLDWIDE SALES
GROWTH ON AN
ORGANIC BASIS*
Q4
$11.5B
Q4
+7.7%1
FULL
$43.1B
FULL
+22.9%
2
YEAR
YEAR
YEAR
$5.21
REFLECTS NEARLY
43%
FULL
3
4
ADJUSTED
GROWTH VERSUS
DILUTED EPS
PRIOR YEAR
LEADING IN HEALTH TECH
$1.0B Q4 FREESTYLE LIBRE®† SALES
Now approaching 4 million users globally
15.8%8 GROWTH IN MEDICAL DEVICES
on an organic basis* compared to pre-pandemic sales in 2019
FULL-YEAR 2021: KEY BUSINESS UNITS5
ADVANCING OUR
GROWTH ON AN ORGANIC BASIS*
VIRTUAL CLINIC
R&D PIPELINE
NEUROSPHERE™
+19.4%
+42.7%
New product introductions and
approvals across our portfolio, including
MEDICAL DEVICES
DIAGNOSTICS
several in large, fast-growing markets
Highlights include expanded
+7.7%
+10.4%
reimbursement coverage for
MitraClip® and launch of NeuroSphere
Virtual Clinic for remote treatment
NUTRITION
ESTABLISHED
chronic pain or movement disorders
PHARMACEUTICALS
ISSUED FULL-YEAR 2022 EPS GUIDANCE
STEPPING U P
AT LEAST
REFLECTS
ON TESTING
the start of the pandemic
$4.70
45%
6
7
More than 1.4 billion COVID
tests distributed globally since
IN ADJUSTED
GROWTH
Excluding COVID-19testing-related
DILUTEDEPS
COMPARED
TO 2019
sales, fourth-quarterDiagnostics sales
increased8.7%9 on an organic basis*
*Organic sales growth excludes impactof foreign exchange. For full financialdata and reconciliation of non-GAAP measures, please see our press release datedJan. 26, 2022, available at www.abbottinvestor.com. 1. On a GAAP basis, fourth-quarterAbbott sales increased 7.2%.
2. On a GAAP basis, full-year 2021 Abbott sales increased 24.5%. 3. Full-year2021 GAAP diluted EPS from continuing operations was $3.94. 4. Full-year 2021 diluted EPS from continuing operations on a GAAP basis reflects 58% growth. 5. On a GAAP basis, full-year 2021
Medical Devices salesincreased 21.9%; Diagnostics sales increased 44.8%; Nutrition sales increased 8.5%; Established Pharmaceuticals sales increased9.6%. 6. Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least $3.43.
Abbott forecastsspecified items for the full-year 2022 of $1.27 per share primarily related to intangible amortization, restructuringand cost reductioninitiatives, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted
earnings pershare from continuing operations would be at least $4.70 for the full-year2022. 7. Ona GAAP basis, full-year2022 projectedadjusted diluted EPS from continuing operations reflects 67% growth compared to 2019. Full-year 2019 diluted EPS from continuing
operationswas $2.06 on a GAAP basis and $3.24 on an adjusted basis.8. Ona GAAP basis, Medical Devices full-year2021sales increased17.0% compared to sales in 2019. 9. On a GAAP basis excluding COVID-19testing-related sales, fourth-quarter Diagnostics sales
increased8.2%. †Find important safety information about the FreeStyle® Libre portfolio: www.freestylelibre.us/safety-information.
FORWARD-LOOKING STATEMENTS
Some statements in this news release may be forward-looking statements for purposes of the Private SecuritiesLitigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technologicaland other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publiclyany revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Attachments
Disclaimer
Abbott Laboratories published this content on 26 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 January 2022 12:45:08 UTC.

source